“Under the terms of the Japan Distribution Agreement, Capricor received an upfront payment of $12.0 million in 2023 and in addition, Capricor will potentially receive additional development and sales-based milestone payments of up to approximately $89.0 millio…”10-Q · May 13, 2026 ↗
Capricor Therapeutics, Inc.
CAPR
Market read
Capricor Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.
- CAPR's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if CAPR's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- CAPR's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
No qualifying supportive evidence was identified.
- Latest annual revenue changed -100.0% year over year.
- Diluted shares increased 32.0% in the latest annual period.
No credible peer-relative valuation comparison is available yet.
Price as of Sep 10, 2026
8.31Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“Upfront payments received in advance of performance are recorded as deferred revenue.”10-Q · May 13, 2026 ↗
“Subject to regulatory approval, Capricor will have the right to receive a share of product revenue which falls between 30 and 50 percent.”10-K · Mar 17, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales — · EV/sales —. Comparisons use only industry-matched filing peers.
No usable price/earnings or price/sales multiple (need a fresh price).
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for CAPR. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for CAPR. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind CAPR
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
TMOThermo Fisher Scientific Inc.supplierMar 17, 2026 ▾
“13 Table of Contents Cell Line License Agreement with Life Technologies On March 7, 2022, Capricor entered into a non-exclusive cell line license agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, Inc., for the supply of c…”
OPYOppenheimer Holdings Inc.partnerNov 10, 2025 ▾
“g under a prospectus supplement for aggregate sales proceeds of up to $150.0 million (the “September 2025 ATM Program”) on September 10, 2025, pursuant to an Equity Distribution Agreement with Piper Sandler and Oppenheimer (collectively, the “Agents”) by whic…”
Depended on by
BCDABioCardia, Inc.competitorMar 24, 2026 ▾
“The industry continues to expand and evolve as an increasing number of competitors and potential competitors enter the market, including AstraZeneca, Bayer, Blue Rock Therapeutics, Bristol-Myers Squibb, Lisata Therapeutics, Capricor Therapeutics, Celixir, Cel…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
CAPR is currently a Leader in the organic co-movement group Exosome Therapeutics & Commerce. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for CAPR; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.